The total number of records retrieved from this search are 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_192	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic nu/nu mice injected intracranially with GBM30 cells 1.0E+5 cells	In-vivo virus concentration5.0E+5 PFU (on 5 day) in total 8 mice	In-vivo toxicityNA	In-vivo result40% mice survived on 28th day	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_193	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubastatin A (TA) at a dose of 1.3 mg per kg body weight (4, 5, 6, 7 and 8 days after tumor implantation)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic nu/nu mice injected intracranially with GBM30 cells 1.0E+5 cells	In-vivo virus concentration5.0E+5 PFU (on 5 day) in total 8 mice	In-vivo toxicityNA	In-vivo result80% mice survived on 28th day	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_357	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)	In-vivo virus concentration1.0E+9 pfu (every 3 days for at total 4 treatments)	In-vivo toxicityNA	In-vivo result41% smaller tumor size compared to the negative control virus AdLacZ	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_358	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with temozolomide (TMZ) intraperitoneally at 50 mg/Kg for five consecutive days	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)	In-vivo virus concentration1.0E+9 pfu (every 3 days for at total 4 treatments)	In-vivo toxicityNA	In-vivo result70% smaller tumor size compared to the negative control virus AdLacZ	Mode of deliveryIntratumorally	Pathway inducedJNK activation induces autophagy	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_359	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with temozolomide (TMZ) intraperitoneally at 50 mg/Kg for five consecutive days	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)	In-vivo virus concentration1.0E+9 pfu (every 3 days for at total 4 treatments)	In-vivo toxicityNA	In-vivo result30% smaller tumor size compared to the negative control virus AdLacZ	Mode of deliveryIntratumorally	Pathway inducedJNK activation induces autophagy	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_376	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice (subcutaneously xenografted with CHLA-20)	In-vivo virus concentration1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)	In-vivo toxicityNA	In-vivo result42% mice survived	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_377	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice (subcutaneously xenografted with CHP-123)	In-vivo virus concentration1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)	In-vivo toxicityNA	In-vivo result63% mice survived	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_378	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice (subcutaneously xenografted with SK-N-AS)	In-vivo virus concentration1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)	In-vivo toxicityNA	In-vivo result0% mice survived	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_379	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice (subcutaneously xenografted with SK-N-BE(2))	In-vivo virus concentration1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)	In-vivo toxicityNA	In-vivo result18% mice survived	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_392	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHomozygous athymic female nude mice (subcutaneously injected with KMC-1 cells suspended in 50 μl Matrigel)	In-vivo virus concentration1.0E+7 PFU	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 30 cubic millimeter compared to control 200 cubic millimeter after 15 days	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26584530
IDOV_749	Virus nameAdenovirus	Virus strainAdAFPp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral mutant with E1A gene driven by AFP promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHepG2 orthotopic liver xenograft tumor in Balb/c athymic nude	In-vivo virus concentrationNA	In-vivo toxicityNA	In-vivo resultReduction in tumor weight to 0.2 g compared to control 0.75 g after 18 days	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_750	Virus nameAdenovirus	Virus strainAdAFPp-E1A-122	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHepG2 orthotopic liver xenograft tumor in Balb/c athymic nude	In-vivo virus concentrationNA	In-vivo toxicityNA	In-vivo resultReduction in tumor weight to 0.2 g compared to control 0.75 g after 18 days	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_751	Virus nameAdenovirus	Virus strainAdTrack	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHepG2 orthotopic liver xenograft tumor in Balb/c athymic nude	In-vivo virus concentrationNA	In-vivo toxicityNA	In-vivo resultReduction in tumor weight to 0.85 g compared to control 0.75 g after 18 days	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_752	Virus nameAdenovirus	Virus strainAdAFPp-E1A-122	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHepG2 subcutaneous liver xenograft tumor in Balb/c athymic nude	In-vivo virus concentrationNA	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 0.8 cubic centimeter compared to control 2.4 cubic centimeter after 15 days	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_838	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic rat xenograft model for C85 cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryDirect injection	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_839	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic rat xenograft model for C86 cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo result4 xenograft model shows partial reduction and 2 shows complete reduction (50% reduction)	Mode of deliveryDirect injection	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_840	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant of both copies of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic rat xenograft model for HCT8 cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo result4 xenograft model shows complete reduction and 4 shows partial reduction (complete reduction)	Mode of deliveryDirect injection	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10428757
IDOV_858	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationRecombinant expressing a peptide	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomevirus expressing a marker peptide (MV-hCEA)	Source of cell lineNatural	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic mouse xenograft model for SKOV3 cell line	In-vivo virus concentration1.0E+7 pfu/ml	In-vivo toxicityNA	In-vivo resultMedian survival time increased by >105 days	Mode of deliverysubcutaneous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12183422
IDOV_859	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationRecombinant expressing a peptide	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomevirus expressing a marker peptide (MV-hCEA)	Source of cell lineNatural	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic mouse xenograft model for SKOV3 cell line	In-vivo virus concentration10⁷pfu/ml	In-vivo toxicityNA	In-vivo resultMedian survival time increased by >80 days	Mode of deliveryintraperitonial	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12183422
IDOV_897	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for Hep 3B cancer cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor nodes after 4 weeks	Mode of deliveryintraperitonial	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_1103	Virus nameAdenovirus	Virus strainZD55-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus expressing ZD55 gene and IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeExpressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nude mice xenograft for SW620 cell line	In-vivo virus concentration5.0E+8 cells per well	In-vivo toxicityNA	In-vivo resultDecrease in tumor volume below 800mm³ as compared to control	Mode of deliveryIntratumoral injection	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1104	Virus nameAdenovirus	Virus strainAd-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus expressing IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeExpressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nude mice xenograft for SW620 cell line	In-vivo virus concentration5.0E+8 cells per well	In-vivo toxicityNA	In-vivo resultDecrease in tumor volume below 600mm³ as compared to control	Mode of deliveryIntratumoral injection	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1105	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nude mice xenograft for SW620 cell line	In-vivo virus concentration5.0E+8 cells per well	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume	Mode of deliveryIntratumoral injection	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1190	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (5mg/kg for 5 days)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for U87MG cells	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction of tumor after 90 days in 20-40% of animals	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1191	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with Temozolomide drug (7.5mg/kg for 5 days)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for U87MG cells	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction of tumor after 90 days in 20-40% of animals	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1665	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing vstat120 gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice, injected with U87deltaEGFR cell line	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultSignificant increase in median survival time of mice	Mode of deliveryIntracranial	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID19844198
IDOV_1666	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing vstat120 gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice, injected with GlideltaEGFR-H2B-RFP cell line	In-vivo virus concentration1.5E+6 cells	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume and increase in median survival time of mice	Mode of deliverySubcutaneously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID19844198
IDOV_1915	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMalignan small cell canine carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for MTH52c cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultSignificant decrease in tumor volume after 42 days	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alpha	Clinical trialNA	PMID20631910
IDOV_2063	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic hsd nude mice xenograft for PLC cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityReduction in tumor volume below 2000mm compared to control after 45 days	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2064	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHuh-7	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic hsd nude mice xenograft for PLC cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityReduction in tumor volume below 3000mm compared to control after 35 days	In-vivo result	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2408	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for MIA PaCa2 cell line	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor weight below 5 mg after 25 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2409	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell linePANC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for MIA PANC-1 cell line	In-vivo virus concentration5 × 10⁷ pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor weight below 200 mg after 25 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2410	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineHPAF-II	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for HPAF-II cell line	In-vivo virus concentration5 × 10⁷ pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor weight below 20 mg after 25 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2411	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineSU.86.86	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for U.86.86 cell line	In-vivo virus concentration5 × 10⁷ pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor weight below 20 mg after 25 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2526	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenografted for PANC-1 cell line(2.0E+6 cells)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultDecrease in tumor volume below 2 after 34 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2527	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenografted for PANC-1 cell line(2.0E+6 cells)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultDecrease in tumor volume below 2 after 34 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2843	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HCT-116 (5.0E+6 cells)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume after 42 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23531320
IDOV_3002	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HCT-116 (2.0E+6 cells)	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 55 days	Mode of deliveryIntratumoral	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3003	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HT-29 (5.0E+6 cells)	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reached 1500mm after day 50	Mode of deliveryIntratumoral	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3004	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with I-131	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HCT-116 (2.0E+6 cells)	In-vivo virus concentration1.0E+4 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume below 100mm after 55 days	Mode of deliveryIntravenous	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3005	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with I-131	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HT-29 (3.0E+9 cells)	In-vivo virus concentration1.0E+4 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume below 300mm after 45 days	Mode of deliveryIntravenous	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_4108	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for STSA-1 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 1000 mm compared to control 2500mm after 42 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4109	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for STSA-1 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 200 mm compared to control 2500mm after 49 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4148	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (160mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for BxPC-3 (5.0E+5)	In-vivo virus concentration5.0E+10 VP per cell	In-vivo toxicityNA	In-vivo resultMedian survival time increased from 22 days to 57 days with combined tretament	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4149	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (160mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for PANC-1 (5.0E+5)	In-vivo virus concentration5.0E+10 VP per cell	In-vivo toxicityNA	In-vivo resultMedian survival time increased from 37 days to 79.5 days with combined tretament	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4190	Virus nameMeasles virus	Virus strainMV-lambda-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing human lambda immunoglobulin chain	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic nude mice xenograft for MDA-231-lu-P4 (1.0E+6 cells)	In-vivo virus concentration2.0E+6 TCID50	In-vivo toxicityNA	In-vivo resultAll mice dead after 100 days	Mode of deliveryIntravenous	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4191	Virus nameMeasles virus	Virus strainMV-lambda-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing human lambda immunoglobulin chain	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Alisertib 30mg/kg for 3 weeks	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic nude mice xenograft for MDA-231-lu-P4 (1.0E+6 cells)	In-vivo virus concentration2.0E+6 TCID50	In-vivo toxicityNA	In-vivo resultMice median survival time increased to 82.5 days compared to control	Mode of deliveryIntravenous	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4192	Virus nameMeasles virus	Virus strainMV-lambda-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing human lambda immunoglobulin chain	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic nude mice xenograft for MDA-231-lu-P4 (2.0E+6), pleural effusion transthoracic cavity	In-vivo virus concentration5.0E+5 TCID50	In-vivo toxicityNA	In-vivo resultMice median survival increased to 57 days	Mode of deliveryTransthoracic	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4193	Virus nameMeasles virus	Virus strainMV-lambda-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing human lambda immunoglobulin chain	Virus aloneYes	Virus in combination with drug/radiationVirus in combination with Alisertib 30mg/kg for 3 weeks	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic nude mice xenograft for MDA-231-lu-P4 (2.0E+6), pleural effusion transthoracic cavity	In-vivo virus concentration5.0E+5 TCID50	In-vivo toxicityNA	In-vivo resultMice median survival increased to 74 days compared to control 57 days	Mode of deliveryTransthoracic	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4438	Virus nameVesicular stomatitis virus	Virus strainRdB	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, no addition of linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismmale athymic nude mice xenograft for A549 (1.0E+7)	In-vivo virus concentration5.0E+9 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become below 600 cubic millimeter after 71 days compared to control 1000	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4439	Virus nameVesicular stomatitis virus	Virus strainRdB-1L-VSVG	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, addition of single linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismmale athymic nude mice xenograft for A549 (1.0E+7)	In-vivo virus concentration5.0E+9 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become below 100 cubic millimeter after 71 days compared to control 1000	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4440	Virus nameVesicular stomatitis virus	Virus strainRdB	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, no addition of linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismmale athymic nude mice xenograft for MCF7 (1.0E+7)	In-vivo virus concentration5.0E+10 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become below 1500 cubic millimeter after 49 days compared to control 4000	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4441	Virus nameVesicular stomatitis virus	Virus strainRdB-1L-VSVG	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, addition of single linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismmale athymic nude mice xenograft for MCF7 (1.0E+7)	In-vivo virus concentration5.0E+10 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become below 600 cubic millimeter after 49 days compared to control 4000	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4505	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for HT1080 (5.0E+6)	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 300 cubic mm after 25 days compared to control 800 cubic mm	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectInduced expression of Type 1 IFN, NK cells and macrophages	Clinical trialNA	PMID27009956
IDOV_4506	Virus nameNewcastle disease virus	Virus strain73T-S-Km	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of HNKMKS sequence in fusogenic site between 111 -116 nucleotide	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for HT1080 (5.0E+6)	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 100 cubic mm after 25 days compared to control 800 cubic mm	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectInduced expression of Type 1 IFN, NK cells and macrophages	Clinical trialNA	PMID27009956
IDOV_4507	Virus nameNewcastle disease virus	Virus strain73T-R-198	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of HNRTKR sequence in fusogenic site between 111 -116 nucleotide	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for HT1080 (5.0E+6)	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 300 cubic mm after 25 days compared to control 800 cubic mm	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectInduced expression of Type 1 IFN, NK cells and macrophages	Clinical trialNA	PMID27009956
IDOV_4508	Virus nameNewcastle disease virus	Virus strain73T-R-198	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of HNRTKR sequence in fusogenic site between 111 -116 nucleotide	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for HT1080 (5.0E+6)	In-vivo virus concentration1.0E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 500 cubic mm compared to control 1000 cubic mm after 25 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectInduced expression of Type 1 IFN, NK cells and macrophages	Clinical trialNA	PMID27009956
IDOV_4631	Virus nameAdenovirus	Virus strainAd5/3-delata 24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 and delta 24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic nude mice xenograft for UPCI SCC 090 (2.0E+6)	In-vivo virus concentration3.5E+11 pfu	In-vivo toxicityNA	In-vivo resultComplete ereduction in tumor volume after 30 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4632	Virus nameAdenovirus	Virus strainAd5/3-CB016	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale athymic nude mice xenograft for UPCI SCC 090 (2.0E+6)	In-vivo virus concentration3.5E+11 pfu	In-vivo toxicityNA	In-vivo resultComplete ereduction in tumor volume after 30 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4698	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice subcutaneous xenograft for CAL27 (1.5E+7)	In-vivo virus concentration2.0E+6 pfu on day 7 and 16	In-vivo toxicityNA	In-vivo resultMice treated with virus shows delayed tumor growth compared to control, one shows complete tumor regression	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4704	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneNo	Virus in combination with drug/radiationVirus combination with ATN-224 (0.7 mg/kg/day) an copper chelator showing synergistic effect	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for UM-SCC-74A (1.5E+7)	In-vivo virus concentration2.0E+6 pfu on day 7	In-vivo toxicityNA	In-vivo resultIncreased in survival time and reduction in tumor volume to below 200 cubic mm comapred to control 700 cubic mm	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4705	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneNo	Virus in combination with drug/radiationVirus combination with ATN-224 (0.7 mg/kg/day) an copper chelator showing synergistic effect	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for CAL27 (1.5E+7)	In-vivo virus concentration2.0E+6 pfu on day 7	In-vivo toxicityNA	In-vivo resultIncreased in survival time and reduction in tumor volume to below 500 cubic mm comapred to control 2000 cubic mm	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_5184	Virus nameTanapoxvirus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice CrlNU-Foxn1 xenograft for cellosaurus cell line 5.0E+6 cells	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth 250 compared to 550 after 34 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27738905
IDOV_5185	Virus nameTanapoxvirus	Virus strainTPV-delta15L	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for 15L gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice CrlNU-Foxn1 xenograft for cellosaurus cell line 5.0E+6 cells	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume compared to 550 after 34 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27738905
IDOV_5186	Virus nameTanapoxvirus	Virus strainTPV-delta66R	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk 66ORF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice CrlNU-Foxn1 xenograft for cellosaurus cell line 5.0E+6 cells	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth 150 compared to 550 after 34 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27738905
IDOV_5187	Virus nameTanapoxvirus	Virus strainTPV-delta15Ldelta66R	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for 15L gene and tk 66R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice CrlNU-Foxn1 xenograft for cellosaurus cell line 5.0E+6 cells	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth 200 compared to 550 after 34 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27738905
IDOV_5638	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human fibroblast HT1080 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regrression in tumor in 11 mice from complete 12 (tumor volume <10mm and >5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5639	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human fibroblast HT1080 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regrression in tumor in 8 mice from complete 9 (tumor volume <10mm and >5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5640	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human fibroblast HT1080 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regrression in tumor in all mice (tumor volume <10mm and >5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5641	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human ovarian carcinoma PA-1 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regrression in tumor in all mice (tumor volume <10mm and >5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5642	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human oral carcinoma KB (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor in 7 mice from all 12 treated (tumor volume <10mm and >5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5643	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human fmelanoma SKMEL (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor in 5 mice from all 8 treated (tumor volume <10mm and >5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5644	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human lung carcinoma A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor in 5 mice from all 8 treated (tumor volume <10mm and >5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5645	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human lung carcinoma A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regrression in tumor in all mice (tumor volume <10mm and >5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5646	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for humanglioblastoma U87MG (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor in 1 mice from all 9 treated (tumor volume <10mm and >5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5647	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human fibroblast HT1080 (10 million)	In-vivo virus concentration1.0E+9 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in all tumor bearing mice (tumor volume <8.5 mm and > 5.5)	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5648	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human fibroblast HT1080 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in all tumor bearing mice (tumor volume <8.5 mm and > 5.5)	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5649	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human fibroblast HT1080 (10 million)	In-vivo virus concentration6.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume in 10 mice out of 11 (tumor volume <8.5 mm and > 5.5)	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5650	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human fibroblast HT1080 (10 million)	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume in 5 mice out of 11 (tumor volume <8.5 mm and > 5.5)	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5651	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for human fibroblast HT1080 (10 million)	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume in 5 mice out of 7 (tumor volume <8.5 mm and > 5.5)	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5652	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration1.5E+9 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 2 mice from total 8 tretated (tumor dimension 8 - 9.5mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5653	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration9.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 7 mice from total 8 tretated (tumor dimension 8 - 9.5mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5654	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 3 mice from total 8 tretated (tumor dimension 8 - 9.5mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5655	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration1.5E+9 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 2 mice from total 6 tretated (tumor volume <300mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5656	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration9.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 3 mice from total 4 tretated (tumor dimension <300mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5657	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 2 mice from total 6 tretated (tumor volume <300mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5658	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 3 mice from total 5 tretated (tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5659	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in all mice(tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5660	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 4 mice from total 5 tretated (tumor volume>300mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5661	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration1.5E+9 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in all mice (tumor dimension 10 - 11.5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5662	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 6 mice from 7 (tumor dimension 10 - 11.5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5663	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 5 mice from 7 (tumor dimension 10 - 11.5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5664	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in 5 mice from 7 (tumor dimension 10 - 11.5 mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5665	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration1.5E+9 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor in all mice (tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5666	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor in 6 mice from 7 (tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5667	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor in 4 mice from 6 (tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5668	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for A375 (10 million)	In-vivo virus concentration3.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor in 4 mice from 6 (tumor volume >300mm)	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5682	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 261.8mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5683	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 248.4mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5684	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 216.8mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968